At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
In Brief
A Phase 1 clinical trial evaluating Atezolizumab, Brachytherapy, and 2 other interventions for Cervical Adenocarcinoma and 10 related conditions. Completed, enrolled 40 participants across 16 sites.
Detailed Summary
This phase I trial studies how well atezolizumab before and/or with standard of care chemoradiotherapy works in immune system activation in patients with stage IB2, II, IIIB, or IVA cervical cancer that has spread to the lymph nodes. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab before and/or with chemoradiotherapy may lower the chance of tumors growing or spreading.
Study Details
Timeline
Interventions
Given IV
Undergo standard of care image guided brachytherapy
Given IV
Undergo standard of care radiation therapy